Related Experiment Video

Updated: Aug 14, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

[Genetic aspects of the action of immunosuppressive agents]

L A Pevnitskiĭ, V M Pisarev, L Iu Telegin

    Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
    |January 1, 1992
    PubMed

    Insights

    Mice strains DBA/2 and BALB/c show consistent differences in sensitivity to various immunosuppressive drugs. This genetic trait influences both in vivo and in vitro immune responses to these agents.

    Area of Science:

    • Immunology
    • Pharmacology
    • Genetics

    Background:

    • Mice strains exhibit varying responses to immunosuppressive drugs.
    • Alkylating agents previously showed differential effects on DBA/2 (sensitive) and BALB/c (resistant) mice.

    Purpose of the Study:

    • To investigate if DBA/2 and BALB/c mice strains maintain differential sensitivity to non-alkylating immunosuppressive agents.
    • To explore the correlation between in vivo and in vitro sensitivity to immunosuppressants across these mouse strains.

    Main Methods:

    • Administered non-alkylating immunosuppressants (cytarabine, cyclosporin A, dexamethasone) to DBA/2 and BALB/c mice.
    • Assessed in vivo immune response.
    • Evaluated in vitro sensitivity of immunocompetent cells.

    Main Results:

    • DBA/2 mice consistently demonstrated high sensitivity to all tested immunosuppressants.
    • BALB/c mice consistently showed low sensitivity to all tested immunosuppressants.
    • In vivo sensitivity directly correlated with in vitro immunocompetent cell sensitivity.

    Conclusions:

    • Genetic factors in DBA/2 and BALB/c mice confer a stable, broad-spectrum sensitivity or resistance to diverse immunosuppressive agents.
    • The observed sensitivity patterns suggest underlying mechanisms influencing immune cell responses across different drug classes.

    More Related Videos

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

    Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

    Published on: November 8, 2015

    In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

    In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

    Published on: August 12, 2017

    Related Concept Videos

    Cell-mediated Immune Responses01:40

    Cell-mediated Immune Responses

    Overview
    Immunodeficiency Diseases01:25

    Immunodeficiency Diseases

    Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
    There are three main causes of immunodeficiency disorders...
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    Drug toxicity: Idiosyncratic Reactions01:16

    Drug toxicity: Idiosyncratic Reactions

    Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...